Unexpected syntheses of seco-cyclopropyltetrahydroquinolines from a radical 5-exo-trig cyclization reaction: Analogs of CC-1065 and the duocarmycins

Molecules

Volumn 9, Issue 3, 2004, Pages 125-133

  Pati, Hari ^a   Howard, Tiffany ^a   Townes, Heather ^a   Lingerfelt, Brian ^a   McNulty, LuAnne ^a   Lee, Moses ^a  

^a FURMAN UNIVERSITY   (United States)

Author keywords

(Chloromethyl)furano e indoline; (Chloromethyl)furano f tetrahydroquinoline; CC 1065; Duocarmycins; seco Cyclopropyltetrahydroquinoline

Indexed keywords

6 BENZYLOXY N TERT BUTOXYCARBONYL 3 (CHLOROMETHYL) 5 METHYLFURAN[E]INDOLINE; 6 BENZYLOXY N TERT BUTOXYCARBONYL 3 (CHLOROMETHYL)FURAN[E]INDOLINE; 6 BENZYLOXY N TERT BUTOXYCARBONYL 3 (CHLOROMETHYL)THIOPHEN[E]INDOLINE; 7 BENZYLOXY N TERT BUTOXYCARBONYL 3 CHLORO 1,2,3,4 TETRAHYDRO 5 METHYLFURANO[F]QUINOLINE; 7 BENZYLOXY N TERT BUTOXYCARBONYL 3 CHLORO 1,2,3,4 TETRAHYDROFURANO[F]QUINOLINE; 7 BENZYLOXY N TERT BUTOXYCARBONYL 3 CHLORO 1,2,3,4 TETRAHYDROTHIOPHENO[F]QUINOLINE; BUTYL 5 [6 BENZYLOXY N TERT BUTOXYCARBONYL 3 (CHLOROMETHYL)BENZ[E]INDOLINE]CARBOXYLIC ACID; BUTYL 5 [7 BENZYLOXY N TERT BUTOXYCARBONYL 3 CHLORO 1,2,3,4 TETRAHYDROBENZO[F]QUINOLINE]CARBOXYLIC ACID; DUOCARMYCIN A; DUOCARMYCIN DERIVATIVE; FREE RADICAL; INDOLE DERIVATIVE; PYRINDAMYCIN A; PYRINDAMYCIN B; QUINOLINE DERIVATIVE; RACHELMYCIN; RACHELMYCIN DERIVATIVE; SECOCYCLOPROPYLTETRAHYDROQUINOLINE; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL REACTION; CYCLIZATION; DNA ALKYLATION; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; PHARMACOPHORE; REACTION ANALYSIS;

EID: 3242815274     PISSN: 14203049     EISSN: None     Source Type: Journal    
DOI: 10.3390/90300125     Document Type: Article

References (32)

1. (a) Li, L.H.; Wallace, T.L.; DeKoning, T.F.; Warpehoski, M.A.; Kelly, R.C.; Prairie, M.D.; Drueger, W.C. Invest. New Drugs 1987, 5, 329;
2. (b) Li, L.H.; Kelly, R.C.; Warpehoski, M.A.; McGovern, J.P.; Gebhard, I.; DeKoning, T.F. Invest. New Drugs 1991, 9, 137;
3. (c) Warpehoski, M. In Advances in DNA Sequence Specific Agents: Hurley, L.H. Ed.; JAI Press, Inc.: Greenwich, CT, 1992; Vol. 1, pp 217-245.
4. (a) Boger, D.L.; Garbaccio, R.M. Acc. Chem. Res. 1999, 32, 1043;
5. (b) Boger, D.L.; Johnson, D.S. Angew. Chem. Int. Ed. Engl. 1996, 35, 1438;
6. (c) Boger, D.L.; Johnson, D.S. Proc. Natl. Acad. Sci. USA 1995, 92, 3642;
7. (d) Boger, D.L. Acc. Chem. Res. 1995, 28, 20;
8. (e) Boger, D.L. Chemtracts: Org. Chem. 1991, 4, 329.
9. Boger, D.L.; Boyce, C.W.; Johnson, D.S. Bioorg. Med. Chem. Lett. 1997, 7, 233.
10. (a) Boger, D.L.; Johnson, D.S.; Wassidlo, W. Bioorg. Med. Chem. Lett. 1994, 4, 631;
11. (b) Wang, Y.; Yuan, H.; Ye, W.; Wright, S.C.; Wang, H.; Larrick, J.W. J. Med. Chem. 2000, 43, 1541.
12. (a) Hightower, R.D.; Sevin, B.U.; Pevras, J.P.; Untch, M.; Angioli, R.; Averette, H. Gynecol. Oncol. 1992, 42, 186;
13. (b) Cote, S.; Momparler, R.L. Anti-Cancer Drugs 1993, 4, 327;
14. (c) Fleming, G.F.; Ratain, S.M.; O'Brien, R.L.; Schilsky, P.C.; Ramos, R.; Richards, J.M.; Vogelzang, N.J.; Kasunic, D.A.; Earhart, R.H. J. Natl. Cancer Inst. 1994, 86, 368;
15. (d) Foster. B.J.; Larusso, P.M.; Poplin, E.; Zalupski, M.; Valdivieso, M.; Wozniak, A.; Flaherty, L.; Kasunic, D.A.; Earhart, R.H.; Baker, L.H. Invest. New Drugs 1996, 13, 321;
16. (e) Burris, H.A.; Dieras, V.C.; Tunca, M.; Earhart, R.H.; Earhart, J.R.; Rodriguez, G.L.; Shaffer, D.S.; Fields, S.M.; Campbell, E.; Schaaf, L.; Kasunic, D.; Von Hoff, D.D. Anti-Cancer Drugs 1997, 8, 588.
17. (a) Li, L.H.; Dekoning, J.F.; Kelly R.C.; Krueger, W.C.; McGovern, J.P.; Padbury, G.E.; Petzold, G.L.; Wallace, T.L.; Ouding, R.J.; Praire, M.D.; Gebhard, I. Cancer Res. 1992, 52, 4904;
18. (b) van Telligen, O.; Punt, C.J.A.; Awada, A.; Wagener, D.J.T.; Piccart, M.J.; Groot, Y.; Schaaf, L.J.; Henrar, R.E.C.; Nooijen, W.J.; Beijnen, J.H. Cancer Chemother. Pharmacol. 1998, 41, 366.
19. (a) Nagamura, S.; Kobayashi, E.; Gomi, K.; Saito, H. Bioorg. Med. Chem. Lett. 1996, 6, 2147, and references therein;
20. (b) Alberts, S.R.; Erlichman, C.; Reid, J.M.; Sloan, J.A.; Ames, M.M.; Richardson, R.L.; Goldberg, R.M. Clin. Cancer Res. 1998, 4, 2111.
21. (a) Walker, D.L.; Reid, F.M.; Ames, M.M. Cancer Chemother. Pharmacol. 1994, 34, 317-322.
22. (b) Volpe, D.A.; Tomaszewski, J.E.; Parchment, R.E.; Garg, A.; Flora, K.P.; Murphy, M.J.; Grieshaber, C.K. Cancer. Chemother. Pharmacol. 1996, 39, 143.
23. (c) Pitot IV, H.C.; Erlichman, C.; Reid, J.M.; Sloan, J.A.; Ames, M.M.; Bagniewski, P.G.; Atherton-Skaaf, P.; Adjei, A.A.; Rubi, J.; Rayson, D.; Goldberg, R.M. Proc. Am. Assoc. Cancer Res. 1999, 40, 91.
24. (a) Boger, D.L.; McKie, J.A. J. Org. Chem. 1995, 60, 1271.
25. (b) Boger, D.L.; Yun, W.; Han, N. Bioorg. Med. Chem. 1995, 3, 1429.
26. Baraldi, P.G.; Cacciari, B.; Pinedo de las Infantas, M.J.; Romagnoli, R.; Spatullo, G.; Cozzi, P.; Mongelli, N. Anti-Cancer Drug Design 1997, 12, 67.
27. (a) Mohamadi, F.; Spees, M.M.; Staten, G.S.; Marder, P.; Kipka, J.K.; Johnson, D.A.; Boger, D.L.; Zarrinmayeh, H. J. Med. Chem. 1994, 37, 232.
28. (b) Patel, V.F.; Andis, S.L.; Enkema, J.K.; Johnson, D.A.; Kennedy, J.H.; Mohamadi, F.; Schultz, R.M.; Soose, D.J.; Spees, M.M. J. Org. Chem. 1997, 62, 8868.
29. (a) Boger, D.L.; Munk, S.A.; Zarrinmayeh, H.; Ishizaki, T.; Haught, J.; Bina, M. Tetrahedron 1991, 47, 2661.
30. (b) Boger, D.L.; Ishizaki, T.; Zarrinmayeh, H.; Munk, S.A.; Kitos, P.A.; Suntorwart, O. J. Am. Chem. Soc. 1990, 112, 8961.
31. Howard, T.T.; Lingerfelt, B.M.; Purnell, B.L.; Scott, A.E.; Price, C.A.; Townes, H.M.; McNulty, L.; Handl, H.L.; Summerville, K.; Hudson, S.J.; Bowen, P.J.; Kiakos, K.; Hartley, J.A.; Lee, M. Bioorg. Med. Chem. 2002, 10, 2941.
32. Boger, D.L.; Boyce, C.W.; Garbaccio, R.M.; Searcey, M. Tetrahedron Lett. 1998, 39, 2227.